- Home
- DRCT vs CANF Comparison
DRCT vs CANF Comparison
Compare DRCT & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRCT
- CANF
- Stock Information
- Founded
- DRCT 2018
- CANF 1994
- Country
- DRCT United States
- CANF Israel
- Employees
- DRCT N/A
- CANF N/A
- Industry
- DRCT Computer Software: Programming Data Processing
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- DRCT Technology
- CANF Health Care
- Exchange
- DRCT Nasdaq
- CANF Nasdaq
- Market Cap
- DRCT 9.2M
- CANF 9.6M
- IPO Year
- DRCT 2022
- CANF N/A
- Fundamental
- Price
- DRCT $0.46
- CANF $0.63
- Analyst Decision
- DRCT Strong Buy
- CANF Strong Buy
- Analyst Count
- DRCT 1
- CANF 2
- Target Price
- DRCT $6.00
- CANF $14.00
- AVG Volume (30 Days)
- DRCT 791.3K
- CANF 140.0K
- Earning Date
- DRCT 08-05-2025
- CANF 08-26-2025
- Dividend Yield
- DRCT N/A
- CANF N/A
- EPS Growth
- DRCT N/A
- CANF N/A
- EPS
- DRCT N/A
- CANF N/A
- Revenue
- DRCT $36,459,000.00
- CANF $560,000.00
- Revenue This Year
- DRCT $16.81
- CANF $461.72
- Revenue Next Year
- DRCT $62.96
- CANF N/A
- P/E Ratio
- DRCT N/A
- CANF N/A
- Revenue Growth
- DRCT N/A
- CANF N/A
- 52 Week Low
- DRCT $0.38
- CANF $0.63
- 52 Week High
- DRCT $6.59
- CANF $3.12
- Technical
- Relative Strength Index (RSI)
- DRCT 48.77
- CANF 29.23
- Support Level
- DRCT $0.44
- CANF $0.64
- Resistance Level
- DRCT $0.48
- CANF $0.68
- Average True Range (ATR)
- DRCT 0.04
- CANF 0.03
- MACD
- DRCT 0.01
- CANF 0.01
- Stochastic Oscillator
- DRCT 75.24
- CANF 2.00
About DRCT Direct Digital Holdings Inc.
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).